Skip the wait and schedule your appointments online or through MyChart.

COVID Vaccine Now Available for Ages 6 months+ – Learn More

Research & Innovation

Colorectal Clinical Trials

Clinical Trials

NRG-GI004

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Physician & Study Coordinator

Physician

Asim Ali, MD

Asim Ali, MD

Study Coordinator

Vivian Colon
484-658-1793

vivian.colon@sluhn.org

Close

Synopsis

Synopsis: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer **Arm 1 (mFOLFOX6 + bevacizumab) is closed to accrual

Close

Eligibility Criteria
  • Is ≥18 years of age, at the time of signing the informed consent
  • Metastatic, previously untreated, adenocarcinoma of colon or rectum
  • dMMR by IHC with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6. Alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
  • Measurable disease per RECIST 1.1
  • No immediate need for surgical intervention

Close